{
    "Trade/Device Name(s)": [
        "TruDiagnosis System",
        "TruDx 2000 Imager",
        "TruArray Warfarin Sensitivity Test Kit",
        "ProFlex PCR System"
    ],
    "Submitter Information": "Akonni Biosystems, Inc.",
    "510(k) Number": "K183530",
    "Predicate Device Reference 510(k) Number(s)": [
        "K073720"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ODW",
        "ODV",
        "NSU"
    ],
    "Summary Letter Date": "May 24, 2019",
    "Summary Letter Received Date": "May 1, 2019",
    "Submission Date": "April 26, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.3360",
        "21 CFR 864.7750",
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Drug metabolizing enzyme genotyping system",
        "Prothrombin time test",
        "Instrumentation for Clinical Multiplex Test Systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "chemistry",
        "toxicology",
        "hematology"
    ],
    "Analyte(s)": [
        "CYP2C9*2 (430C>T)",
        "CYP2C9*3 (1075A>C)",
        "VKORC1 (-1639G>A)"
    ],
    "Specimen Type(s)": [
        "Genomic DNA from human saliva"
    ],
    "Specimen Container(s)": [
        "Oragene Dx Device (OGD-500)"
    ],
    "Instrument(s)/Platform(s)": [
        "TruDx 2000 Imager",
        "ProFlex PCR System"
    ],
    "Method(s)/Technology(ies)": [
        "PCR",
        "On-slide gel-drop microarray",
        "Asymmetric PCR",
        "Fluorescence detection",
        "Microarray-based hybridization"
    ],
    "Methodologies": [
        "Genotyping",
        "Allele-specific hybridization"
    ],
    "Submission Type(s)": [
        "System",
        "Instrument",
        "Assay",
        "Reagent",
        "Software",
        "Test Kit"
    ],
    "Document Summary": "FDA 510(k) summary for the Akonni TruDiagnosis System, an in vitro diagnostic system using on-slide PCR gel-drop microarray technology to genotype CYP2C9 and VKORC1 variants from human saliva DNA.",
    "Indications for Use Summary": "Intended for processing and genotyping multiple genetic variants (CYP2C9*2, CYP2C9*3, VKORC1 -1639G>A) from DNA in human saliva using on-slide PCR gel-drop microarray technology to aid identification of patients at risk for increased warfarin sensitivity.",
    "fda_folder": "Toxicology"
}